These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 21288057)

  • 1. Respiratory-related medical expenditure and inpatient utilisation among COPD patients receiving long-acting bronchodilator therapy.
    Cao Z; Zou KH; Baker CL; Su J; Paulose-Ram R; Durden E; Shi N; Shah H
    J Med Econ; 2011; 14(2):147-58. PubMed ID: 21288057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rehospitalization risks and outcomes in COPD patients receiving maintenance pharmacotherapy.
    Dalal AA; Shah M; D'Souza AO; Crater GD
    Respir Med; 2012 Jun; 106(6):829-37. PubMed ID: 22425138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management.
    Roberts M; Mapel D; Petersen H; Blanchette C; Ramachandran S
    J Med Econ; 2011; 14(6):769-76. PubMed ID: 21942463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare costs associated with initial maintenance therapy with fluticasone propionate 250 μg/salmeterol 50 μg combination versus anticholinergic bronchodilators in elderly US Medicare-eligible beneficiaries with COPD.
    Dalal AA; Petersen H; Simoni-Wastila L; Blanchette CM
    J Med Econ; 2009; 12(4):339-47. PubMed ID: 19827993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and economic outcomes associated with the use of fluticasone propionate 250 mcg and salmeterol 50 mcg combination versus tiotropium bromide 18 mcg as initial maintenance treatment for chronic obstructive pulmonary disease in managed care.
    Bell CF; Coutinho AD; Farrelly E; Lokhandwala T; Landsman-Blumberg P
    J Med Econ; 2018 Jun; 21(6):629-638. PubMed ID: 29577787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.
    Rascati KL; Akazawa M; Johnsrud M; Stanford RH; Blanchette CM
    Clin Ther; 2007 Jun; 29(6):1203-13. PubMed ID: 17692734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting.
    Perrone V; Sangiorgi D; Buda S; Degli Esposti L
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2749-2755. PubMed ID: 27853362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A US database study characterizing patients initiating a budesonide-formoterol combination versus tiotropium bromide as initial maintenance therapy for chronic obstructive pulmonary disease.
    Kern DM; Williams SA; Tunceli O; Wessman C; Zhou S; Pethick N; Elhefni H; Trudo F
    Int J Chron Obstruct Pulmon Dis; 2014; 9():775-83. PubMed ID: 25071369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments.
    Trudo F; Kern DM; Davis JR; Tunceli O; Zhou S; Graham EL; Strange C; Williams SA
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2055-66. PubMed ID: 26451101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease.
    Dalal AA; Roberts MH; Petersen HV; Blanchette CM; Mapel DW
    Int J Chron Obstruct Pulmon Dis; 2010 Dec; 6():13-22. PubMed ID: 21311689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporating tiotropium into a respiratory therapist-directed bronchodilator protocol for managing in-patients with COPD exacerbations decreases bronchodilator costs.
    Drescher GS; Carnathan BJ; Imus S; Colice GL
    Respir Care; 2008 Dec; 53(12):1678-84. PubMed ID: 19025702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary disease.
    Chatterjee A; Shah M; D'Souza AO; Bechtel B; Crater G; Dalal AA
    Respir Res; 2012 Feb; 13(1):15. PubMed ID: 22340019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone.
    Kurashima K; Hara K; Yoneda K; Kanauchi T; Kagiyama N; Tokunaga D; Takayanagi N; Ubukata M; Sugita Y
    Respirology; 2009 Mar; 14(2):239-44. PubMed ID: 19210650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
    Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
    Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
    Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
    Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes and costs associated with initial maintenance therapy with fluticasone propionate-salmeterol xinafoate 250 microg/50 microg combination versus tiotropium in commercially insured patients with COPD.
    Dalal AA; Candrilli SD; Davis KL
    Manag Care; 2011 Aug; 20(8):46-50, 53-5. PubMed ID: 21887993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study.
    Jung KS; Park HY; Park SY; Kim SK; Kim YK; Shim JJ; Moon HS; Lee KH; Yoo JH; Lee SD; ;
    Respir Med; 2012 Mar; 106(3):382-9. PubMed ID: 21975275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Which long-acting bronchodilator is most cost-effective for the treatment of COPD?
    Hoogendoorn M; Kappelhoff BS; Overbeek JA; Wouters EF; Rutten-van Mölken MP
    Neth J Med; 2012 Oct; 70(8):357-64. PubMed ID: 23065983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association between inhaled long-acting bronchodilators and less in-hospital care in newly-diagnosed COPD patients.
    Kim J; Kim K; Kim Y; Yoo KH; Lee CK; Yoon HK; Kim YS; Park YB; Lee JH; Oh YM; Lee SD; Lee SW
    Respir Med; 2014 Jan; 108(1):153-61. PubMed ID: 23993445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
    Blais L; Forget A; Ramachandran S
    Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.